Medicenna Therapeutics Reports Second Quarter Fiscal 2027 Financial Results and Provides Corporate Update
Key Highlights
- ➤MDNA11 ABILITY-1 enrollment completed with 152 patients globally.
- ➤MDNA11 achieved 40% ORR and 80% DCR in gastrointestinal cancers.
- ➤Bizaxofusp median overall survival reached 13.7 months versus 6.2-month control.
- ➤MDNA209 extended median survival to 23.5 and 26 days versus 7 days in models.
- ➤September cash fell to $3.7 million; resources insufficient for next twelve months.
Expert Statements
Fahar Merchant, President and Chief Executive Officer of Medicenna
“Since the end of our second quarter, Medicenna has delivered a series of important clinical and preclinical readouts across MDNA11, bizaxofusp and MDNA209.”
Fahar Merchant, President and Chief Executive Officer of Medicenna
“ABILITY-1 is now fully enrolled, and the Society for Immunotherapy of Cancer 2026 Annual Meeting (SITC) results provide compelling evidence of durable activity with MDNA11 in heavily pretreated gastrointestinal cancers, including patients whose disease had progressed on prior checkpoint therapy and patients with active liver metastases.”
Fahar Merchant, President and Chief Executive Officer of Medicenna
“The melanoma data were similarly encouraging, with ORRs of 30% and 38% in protocol-defined secondary- and primary-ICI-resistant expansion cohorts, respectively, despite a majority of patients having previously received both PD-1 and CTLA-4 therapy.”
Fahar Merchant, President and Chief Executive Officer of Medicenna
“At the 31st Annual Meeting of the Society for Neuro-Oncology (SNO), bizaxofusp showed encouraging survival in the Phase 3-relevant population, while MDNA209 demonstrated compelling preclinical proof-of-concept in autoimmune disease.”
Fahar Merchant, President and Chief Executive Officer of Medicenna
“These results position us to focus on regulatory engagement for MDNA11 while advancing partnership opportunities for bizaxofusp and MDNA209 and progressing MDNA113 with the near term objective to strengthen our balance sheet and achieve our near term value inflection milestones.”
MDNA11 Phase 1/2 ABILITY-1 completes 152-patient enrollment and demonstrates 40% objective response rate (ORR) and 80% disease control rate (DCR) in biomarker-enriched gastrointestinal cancers
The melanoma data were similarly encouraging, with ORRs of 30% and 38% in secondary and primary ICI-resistant expansion cohorts treated with MDNA11 alone or in combination with pembrolizumab, respectively, with a majority of patients having Stage-4 disease and previously failed both PD-1 and CTLA-4 therapy
Get started
Create a free account to read the full story.
